NASD · Healthcare · Biotechnology · USA
Travere Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Travere Therapeutics is a biopharmaceutical company that develops and delivers treatments for rare kidney and metabolic diseases. The company markets FILSPARI, an oral medication approved to slow kidney function decline in primary IgAN, and has additional candidates in clinical development for other rare kidney conditions. Travere serves patients globally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Travere Therapeutics Inc stock.
Overvalued: intrinsic value $23.72 per share, market price $50.49, margin of safety -112.9% (as of 2026-10-19).
A 4.2x revenue multiple, discounted for its losses, values the shares at $23.72; the price of $50.49 is 113% above that value.
Leak Score: 31/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
59 more in this industry show a wider margin of safety.
TVTX is overvalued (as of the 2026-10-19 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $23.72; the price of $50.49 is 113% above that value.
$23.72 per share (as of the 2026-10-19 close), against a market price of $50.49. That is a margin of safety of -112.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
31 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.